{"Clinical Trial ID": "NCT00256243", "Intervention": ["INTERVENTION 1:", "- Chemotherapy with GM-CSF", "Doxorubicin and cyclophosphamide (AC) Follow-up of weekly treatment with carboplatin/Paclitaxel with GM-CSF (day 2-6) This treatment consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented."], "Eligibility": ["\u2022 Eligibility criteria:", "Patients should be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast cancer. Histological confirmation should be either by biopsy of the heart of the needle or by incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented.", "Patients should meet one of the following criteria (specify one):", "A selected stage IIB disease (T3, N0, M0) or IIIA (T3, N1-2, M0) considered primarily not resealable by an experienced breast surgeon; or otherwise considered appropriate for neoadjuvant treatment.", "B. Stage IIIB (T4, any N, M0 disease) or (any T, N3, M0 disease).", "The physical examination, chest X-rays and all X-rays or analyses necessary for the evaluation of tumours must be performed within 90 days of registration.", "Patients with a clinical diagnosis of congestive heart failure or angina in the chest are NOT eligible. Patients with hypertension or above 60 years of age should be subjected to a multidose (MUGA) or echocardiogram analysis within 90 days of registration (not applicable (NA) if no MUGA is required) and the left ventricular ejection fraction (LVEF) % should be above the lower limit of institutional normal.", "Patients should have serum creatinine and bilirubin the upper institutional limit of normal, and serum glutamic oxaloacetic transaminase (SGOT) or serum pyruvic transaminase (SGPT) 2x the upper institutional limit of normal, which should have been tested within 90 days prior to registration.", "Patients should have an absolute neutrophil count (NAC) of 1500/\u03bcl and a platelet count of 100,000/\u03bcl. These tests should have been performed within 90 days of registration.", "Patients should have a performance status of 0-2 according to the Zubrod criteria.", "Pregnant or lactating women may not participate in this treatment because of the possibility of fetal harm or harm to breast-fed infants. Women with reproductive potential may only participate in this treatment if they have agreed to use an effective contraceptive method.", "All patients should be informed of the experimental nature of this study and should sign and give written informed consent in accordance with institutional and federal guidelines."], "Results": ["Performance measures:", "Clinical response rate", "Clinical response (CR): normal breasts on physical examination. No mass, no thickening, no erythema, no orange skin.", "Time limit: 5 years", "Results 1:", "Title of the arm/group: Chemotherapy with GM-CSF", "Doxorubicin and Cyclophasphamide (AC) Follow-up of carboplatin/Paclitaxel weekly with GM-CSF (day 2-6) This regimen consists of the intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, carboplatin/paclitaxel weekly will be administered for 3 weeks, followed by a week of rest, for a total of 12. Each clinical visit will last approximately 1 hour.", "Total number of participants analysed: 47", "Type of measure: Number of participants", "Unit of measure: Participants 47 100.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/38 (0.00 per cent)"]}